News Contact Us Careers Get E-Mail alerts Search

ADMA Biologics, Inc.

  • Home
  • About Us
    • About ADMA Biologics
    • What We Do
    • Who We Are
      • Senior Leadership Team
      • Board of Directors
      • Scientific Advisory Board
      • Compliance
  • Our Products
    • Products Overview
    • About Primary Immunodeficiency Disease (PI)
    • ASCENIV™
    • BIVIGAM®
    • Nabi-HB®
  • Our Pipeline
  • Immunotechnology
  • Plasma & IVIG
  • Medical Affairs
    • Medical Affairs Overview
    • Publications
  • Investors
    • Overview
    • Press Releases
      • Email Alerts
    • Company Info
      • Profile
      • Presentation
      • Management Team
      • Contacts
      • FAQ
    • Analyst Coverage
    • Events & Webcasts
    • Financial Info
      • Balance Sheets
      • Income Statement
      • Cash Flow
      • Financial Results
      • Annual Reports
    • Stock Info
      • Stock Data & Quote
      • Charts
      • Historical Data
    • SEC Filings
      • SEC Filings
      • Annual Reports
      • Quarterly Reports
      • Section 16 Filings
    • Governance
      • Board of Directors
      • Board Committees
      • Documents
  • News
  • Contact Us
  • Careers
  • Get E-Mail alerts
  • Search

You are now leaving www.admabiologics.com

The link you have selected will take you outside of ADMA Biologics corporate website. The site you will be entering is intended for U.S. audiences only. Do you wish to continue?

Yes No

News

See below for our most recent and archived news events.

Investors

Investors

  • Overview
  • Press Releases
    • Email Alerts
  • Company Info
    • Profile
    • Presentation
    • Management Team
    • Contacts
    • FAQ
  • Analyst Coverage
  • Events & Webcasts
  • Financial Info
    • Balance Sheets
    • Income Statement
    • Cash Flow
    • Financial Results
    • Annual Reports
  • Stock Info
    • Stock Data & Quote
    • Charts
    • Historical Data
  • SEC Filings
    • SEC Filings
    • Annual Reports
    • Quarterly Reports
    • Section 16 Filings
  • Governance
    • Board of Directors
    • Board Committees
    • Documents
  • home Home
  • Investors
  • Press Releases
  • Press Releases

  • Email Alerts

Click below for current and archived news related to the company.

ADMA Biologics Provides Update on Global Intellectual Property Portfolio

Dec 09, 2021 7:00am EST

ADMA Biologics Senior Vice President of Plasma Services Cyndi Tolman Elected to PPTA Source Board of Directors

Nov 17, 2021 7:00am EST

ADMA Biologics Advances Plasma Collection Center Expansion Plans with Opening of New Facility in Myrtle Beach, SC

Nov 16, 2021 7:00am EST

ADMA Biologics Reports Record Third Quarter 2021 Financial Results and Highlights Recent Progress and Accomplishments

Nov 10, 2021 4:01pm EST

ADMA Biologics to Report Third Quarter 2021 Financial Results on November 10, 2021

Nov 03, 2021 7:00am EDT

ADMA Biologics Announces Closing of $57.5 Million Public Offering Including Full Exercise of Underwriters’ Option to Purchase Additional Shares

Oct 25, 2021 4:01pm EDT

ADMA Biologics Announces Data Presented at the 2021 ISIRV-WHO Conference

Oct 22, 2021 7:00am EDT

ADMA Biologics Announces Pricing of Public Offering for $50 Million of Common Stock

Oct 21, 2021 9:00am EDT

ADMA Biologics Announces Proposed Public Offering of Common Stock

Oct 20, 2021 4:01pm EDT

ADMA Biologics Announces a Poster Presentation at the 2021 International Society for Influenza and other Respiratory Virus Diseases - World Health Organization Conference

Oct 19, 2021 7:00am EDT
RSS
  • Prev
    • 1
    • 2
    • 3
    • 4
    • 5
    • 6
    • 7
    • 8
    • 9
    • 10
    • ...23
    Next
    About Us Our Products Our Pipeline Inmunotechnology Plasma & IVIG Medical Affairs Investors Privacy Policy Disclaimer Sitemap Contact Us Connect with Us Email Alerts RSS

    © Copyright 2022 ADMA Biologics, Inc.
    Ramsey, NJ Offices 201-478-5552
    Boca Raton, FL Offices 561-989-5800
    info@admabio.com

    Best places to work
    Bio NJ

    2020 Innovator Award

    50 fastest companies
    2019 Fast 500 Deloitte
    Bio Florida

    Named 2019 Company of the Year